Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WNT 974

Next Previous
Search
Drug Profile

WNT 974

Alternative Names: LGK-974; NVP-LGK974; WNT-974

Latest Information Update: 19 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Array BioPharma; Novartis; Novartis Oncology
  • Class Acetamides; Antineoplastics; Pyrazines; Pyridines; Small molecules
  • Mechanism of Action PORCN protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer
  • Phase I Solid tumours

Most Recent Events

  • 19 Dec 2024 Chemical structure information added.
  • 13 Sep 2024 Efficacy and adverse events data from a phase I trial in Cancer presented at the at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 17 Jun 2024 Phase-I development in Solid-tumours (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) is ongoing in USA (PO), Spain (PO), Netherlands (PO) (NCT01351103)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top